Quantcast
Channel: www.hivandhepatitis.com - HCV Treatment
Browsing latest articles
Browse All 94 View Live

Image may be NSFW.
Clik here to view.

Merck Discontinues Development of Experimental Hepatitis C Drugs

Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor...

View Article


Image may be NSFW.
Clik here to view.

AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis

Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people...

View Article


Image may be NSFW.
Clik here to view.

AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life

People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to...

View Article

Image may be NSFW.
Clik here to view.

Coverage of the 2017 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017. Conference highlights include direct-acting...

View Article

Image may be NSFW.
Clik here to view.

AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a...

View Article


Image may be NSFW.
Clik here to view.

AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a...

View Article

Image may be NSFW.
Clik here to view.

AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C...

Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down,...

View Article

Image may be NSFW.
Clik here to view.

AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan

Treatment of chronic hepatitis C with direct-acting antivirals can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modeling...

View Article


Coverage of IDWeek 2017

HIVandHepatitis.com coverage of IDWeek 2017, held October 4-8, 2017, in San Diego. Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV Single-Tablet Protease Inhibitor Regimen...

View Article

Browsing latest articles
Browse All 94 View Live